{"resourceType":"MedicinalProductIndication","id":"example","meta":{"versionId":"1","lastUpdated":"2023-12-05T15:41:44.403+00:00","security":[{"system":"http://terminology.hl7.org/CodeSystem/v3-ActReason","code":"HTEST","display":"test health data"}]},"text":{"status":"generated","div":"
\n Generated Narrative with Details\n
\n\n id: example
\n\n diseaseSymptomProcedure: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip\\nor knee replacement surgery.\\nPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation\\n(NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age\\n≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).\\nTreatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent\\nDVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). (Details : {http://ema.europa.eu/example/indicationasdisease-symptom-procedure code 'Venousthromboembolismprophylaxis' = 'Venousthromboembolismprophylaxis)
\n\n comorbidity: Hipsurgery (Details : {http://ema.europa.eu/example/comorbidity code 'Hipsurgery' = 'Hipsurgery)
\n\n intendedEffect: PRYLX (Details : {http://ema.europa.eu/example/intendedeffect code 'PRYLX' = 'PRYLX)
\n\n population:
\n